Hepatitis :: Positive opinion for hepatitis B drug Sebivo
On 22 February 2007 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending to grant a marketing authorisation for the medicinal product Sebivo, 600 mg, film-coated tablet intended for treatment of chronic hepatitis B virus (HBV) infection in adult patients.